(2R,6R)-Hydroxynorketamine

(2R,6R)-Hydroxynorketamine, usually shortened to (2R,6R)-HNK, is one of twelve hydroxynorketamines the body makes from ketamine. Ketamine is first N-demethylated to norketamine, then hydroxylated on the cyclohexyl ring; the (2R,6R) stereoisomer is the one that reaches brain in quantity and the one the antidepressant literature is about ^[6].

It matters because of what it appears to do without. Ketamine's antidepressant effect has always travelled with dissociation, a rise in blood pressure, and real abuse liability, and the standard explanation for all of it was NMDA receptor blockade. In 2016 a Nature paper reported that blocking ketamine's conversion to HNK abolished its sustained antidepressant-like effect in mice, while HNK given on its own reproduced that effect without the dissociation-like or reward-like behaviour ^[1]. A follow-up measured the metabolite directly against NMDA receptor function and found no meaningful block at antidepressant-relevant concentrations ^[2]. Instead the effect tracks a rise in AMPA receptor throughput, BDNF release and synaptic strengthening, with a contribution from mGlu2 receptors on the glutamate terminal ^[3].

The honest position is that this is a strong hypothesis, not a settled result. Independent groups have failed to reproduce the behavioural effect: one found no antidepressant action in a rat learned-helplessness model where (R)-ketamine worked ^[4], and another found none of the metabolites active in a chronic corticosterone model at doses up to 20 mg/kg ^[5]. The disagreement is public and has been argued in print ^[6]. No trial has yet reported human antidepressant efficacy, so everything above is animal pharmacology.

There is no human safety record to report, which is the single most important thing to know about it. Everything published is rodent pharmacology, so any statement about tolerability in people would be an extrapolation rather than an observation.

What the preclinical work does show is an absence: at antidepressant-relevant doses (2R,6R)-HNK did not produce the dissociation-like behaviour, the motor changes or the reward-related responses that ketamine produces in the same assays, and it did not substitute for ketamine on measures used to predict abuse liability ^[1]. That absence is the reason the compound is interesting, and it is also exactly the kind of finding that needs replication before it is treated as a property. Because the molecule does not appear to block NMDA receptors at active concentrations, the harms that follow repeated NMDA blockade in heavy ketamine use, the ulcerative cystitis and the cognitive complaints, have no obvious mechanism here; that is a reasoned expectation and not a measured result.

The compound existed as an analytical curiosity long before it was interesting. Ketamine's metabolic route to norketamine and then to hydroxylated norketamines had been described for decades, and the hydroxynorketamines were treated as inactive end products on the way out of the body ^[6].

That changed in 2016. A group at the National Institute of Mental Health and the University of Maryland reported in Nature that ketamine's sustained antidepressant-like action in mice depended on its conversion to (2S,6S;2R,6R)-HNK, that the (2R,6R) isomer alone reproduced the effect, and that it did so without the dissociation-like and reward-like behaviours ketamine produced ^[1]. The claim was immediately contested in the same literature, with published exchanges over whether the metabolite or the parent drug carries the effect ^[6].

The following years produced both support and contradiction. A 2019 paper located an mGlu2 receptor dependence for the effect ^[3] and a companion paper established that the metabolite does not block NMDA receptors at the concentrations involved ^[2]. Against that, a 2017 rat learned-helplessness study found no antidepressant effect at all where (R)-ketamine worked ^[4], and a 2020 chronic corticosterone study found none of the metabolites effective ^[5]. The question is still open.

Among people who follow rapid-acting antidepressant research, (2R,6R)-HNK is discussed less as a drug than as a test of an idea: that the dissociation is a side effect rather than the mechanism. That framing is what gives it outsized attention relative to its evidence base.

Outside that literature it is barely known, and it is not something that circulates. It is not sold as a supplement or a research chemical, no consumer-facing product contains it, and there is no established human dose to talk about, so the folklore that surrounds ketamine has never attached itself here. The most common error in casual discussion is treating the 2016 Nature result as settled; the replication record does not support that, and the papers that failed to reproduce it are less cited than the one that produced it.